• Nelfinavir Mesylate: DDI2 and Ferroptosis

  2026-10-07

  Nelfinavir Mesylate is best known as an HIV-1 protease inhibitor, but a 2025 Cell Death & Differentiation study examined its use as a pharmacological perturbation of the DDI2–NFE2L1 proteostasis pathway during ferroptosis. This overview separates the established antiviral context from the newer mechanistic findings, compares the strength of genetic and chemical evidence, and outlines limitations affecting interpretation and translational relevance.

• SERCA2–FABP4 Signaling in Atherosclerosis

  2026-10-06

  A 2025 British Journal of Pharmacology study identifies the calcineurin/FoxO1/FABP4 axis as a mechanistic link between SERCA2 dysfunction, altered lipid handling, foam cell formation, and atherosclerosis. Its mouse and macrophage evidence supports FABP4 inhibition as a research strategy, while model-specific limitations mean the findings should not be treated as clinical validation.

• Vancomycin Hydrochloride in Microbiology Research

  2026-10-06

  A source-grounded overview of vancomycin hydrochloride, covering its glycopeptide mechanism, research applications, resistance evidence, Clostridioides difficile models, comparative interpretation, and key limitations.

• Thrombin B Chain Fragment: Evidence and Scope

  2026-10-05

  Explore how the Coagulation Factor II (Thrombin) B Chain Fragment differs from active thrombin and what that distinction means for interpreting coagulation and protease research. This evidence-focused guide also clarifies what the SARS-CoV-2 3CLpro inhibitor study does—and does not—demonstrate about thrombin-related materials.

• Thrombin Biology, Evidence, and Research Context

  2026-10-05

  A source-grounded overview of thrombin as a coagulation cascade enzyme, the evidentiary limits of a short thrombin B-chain fragment, and why a SARS-CoV-2 protease study should not be interpreted as evidence for thrombin activity or therapeutic use.

• LY2109761 and TGF-β Signaling: Evidence Overview

  2026-10-04

  LY2109761 is described by APExBIO as a TGF-β receptor type I and II dual inhibitor for research on Smad signaling, cancer biology, fibrosis, and cellular plasticity. This overview separates supplier-reported properties from findings in the supplied glioblastoma study, which evaluated resveratrol rather than LY2109761, and explains what the available evidence can—and cannot—support.

• Sulfisomidine: hPON1 and Microbial Workflows

  2026-10-01

  Sulfisomidine, also known as sulfamethin, connects bacterial folate-pathway experiments with mechanistic human serum paraoxonase 1 studies. This workflow-focused guide explains stock preparation, mixed-type inhibition analysis, microbial testing, troubleshooting, and responsible cross-domain interpretation.

• AEBSF.HCl: From Protease Control to Translation

  2026-10-01

  AEBSF.HCl, or 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, is more than a routine serine protease inhibitor. Used with appropriate orthogonal controls, it can help translational researchers separate serine-protease-dependent biology from the lysosomal cathepsin axis that drives MLKL-associated necroptosis, while also supporting amyloid precursor protein and cell-lysis studies.

• Amplex Red Workflows for H2O2 and HRP Assays

  2026-09-30

  Amplex Red turns hydrogen peroxide formation into a quantitative resorufin signal for oxidase, HRP, cellular ROS, and enzyme-immobilization studies. This practical guide combines plate-based assay design with the reference study’s nanoelectrode workflow, emphasizing calibration, controls, and troubleshooting.

• Antimycin A4: Dual-Pathway Research Workflows

  2026-09-30

  Antimycin A4 enables parallel investigation of ATP-citrate lyase activity, lipid precursor supply, and mitochondrial electron transport. This practical guide separates those effects with enzyme-first controls, cell-based validation, storage guidance, and troubleshooting logic.

• Grazoprevir Hydrate: From Target to Assay

  2026-09-29

  Grazoprevir hydrate is an HCV NS3/4A protease inhibitor with genotype-sensitive antiviral potency and strong translational value. This article connects mechanism, pharmacokinetics, clinical context, and assay design to support more rigorous hepatitis C research decisions.

• Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor

  2026-09-29

  The reference study screened approximately 6,000 compounds and identified merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro/Mpro. Enzyme kinetics, binding assays, and molecular docking supported a mixed-type mechanism involving more than one binding site, providing a useful framework for validating antiviral protease inhibitors.

• Vancomycin Hydrochloride: Mechanism to Translation

  2026-09-28

  A mechanism-first guide to using Vancomycin hydrochloride as a Gram-positive benchmark, resistance probe, and translational research tool.

• BMS 309403: Testing FABP4 Causality in Foam Cells

  2026-09-28

  BMS 309403 is a potent FABP4 inhibitor for probing how fatty-acid handling contributes to macrophage foam-cell formation. This article focuses on what the 2025 SERCA2 study adds to experimental design: a way to distinguish upstream calcium-signaling defects from downstream FABP4-dependent lipid phenotypes.

• Z-LEHD-FMK: Caspase-9 Inhibition in Research

  2026-09-27

  Z-LEHD-FMK is an irreversible caspase-9 inhibitor used to probe caspase-9-dependent apoptosis. This article distinguishes the compound’s vendor-described uses from the chicken GSDME study, which examines RNA-virus-induced pyroptosis and does not test Z-LEHD-FMK.

534 records 1/36 page Next 12345 下5页 Last page